Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CTFA on VOCs, antimicrobials

This article was originally published in The Rose Sheet

Executive Summary

The Cosmetic, Toiletry and Fragrance Association requested extension to submit comments on volatile organic compound fees to California Air Resources Board beyond May 14 deadline, association says. Comments will be sent to CARB "within weeks," CTFA adds. CARB workgroup plans to present a regulation proposal to the air resources board for adoption in July (1"The Rose Sheet" May 5, 2003, p. 3). Separately, FDA is unable to respond to CTFA/SDA 2001 citizen petition on antimicrobials by 180-day deadline due to "existence of other priorities," agency states in April 16 letter to CTFA and the Soap and Detergent Association. CTFA/SDA petitioned the agency to reopen rulemaking for the tentative final monograph for OTC health care antiseptic drug products to consider a comprehensive literature review with current scientific data (2"The Rose Sheet" Aug. 13, 2001, p. 9)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

RS011207

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel